Dashboard
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 7.24%
- Poor long term growth as Operating profit has grown by an annual rate -2.00% of over the last 5 years
- NET SALES(Q) Highest at Rs 47.67 cr
- PBDIT(Q) Highest at Rs 8.61 cr.
- OPERATING PROFIT TO NET SALES(Q) Highest at 18.06%
Stock is technically in a Bullish range
With ROCE of 6.6, it has a Very Expensive valuation with a 8.3 Enterprise value to Capital Employed
Despite the size of the company, domestic mutual funds hold only 0% of the company
Stock DNA
Pharmaceuticals & Biotechnology
INR 1,135 Cr (Micro Cap)
97.00
40
0.00%
0.35
11.16%
11.00
Total Returns (Price + Dividend) 
Latest dividend: 5.999999999999999 per share ex-dividend date: Sep-19-2013
Risk Adjusted Returns v/s 
Returns Beta
News

Bafna Pharmaceuticals Ltd is Rated Hold
Bafna Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 November 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 21 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Bafna Pharmaceuticals Ltd Reports Strong Quarterly Performance Amid Financial Trend Reversal
Bafna Pharmaceuticals Ltd has delivered its highest quarterly performance to date in September 2026, marking a significant turnaround from previous negative financial trends. Despite a recent downgrade in market sentiment, the company’s latest results reveal robust revenue growth, margin expansion, and improved profitability metrics, signalling a potential inflection point for this micro-cap player in the Pharmaceuticals & Biotechnology sector.
Read More
Bafna Pharmaceuticals Ltd Hits New 52-Week High of Rs 504 on Back of Strong Technical Signals
From a 52-week low of Rs 95 to a fresh peak of Rs 504, Bafna Pharmaceuticals Ltd has surged an impressive 172.21% over the past year, significantly outperforming the Sensex which declined by 3.21% in the same period. This remarkable rally culminated in the stock hitting an all-time high today, driven predominantly by a broad alignment of technical indicators signalling sustained momentum.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSEWe herewith enclose the Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter & Half Year ended September 30 2026 as published in Business Standard and Makkal Kural on November 13 2026.
Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026
11-Nov-2026 | Source : BSEWe herewith enclose the Unaudited Financial Results for the Quarter and Half Year ended September 30 2026 as approved by the Board of Directors in its Meeting held on November 11 2026.
Board Meeting Outcome for The Board Meeting Held On 11/11/2026
11-Nov-2026 | Source : BSEWe hereby inform you that the Board of Directors in its Meeting held on November 11 2026 inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the Quarter and Half Year ended September 30 2026.
Corporate Actions 
No Upcoming Board Meetings
Bafna Pharmaceuticals Ltd has declared 6% dividend, ex-date: 19 Sep 13
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 3 FIIs (9.34%)
Srjr Lifesciences Llp (74.57%)
Cullinan Opportunities Fund Vcc-cullinan Opportunities Incorporated Vcc Sub Fund 1 (3.21%)
11.97%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 79.35% vs -37.07% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 8,462.50% vs -97.09% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -4.78% vs -10.92% in Sep 2024
Growth in half year ended Sep 2025 is 244.44% vs -78.60% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 1.48% vs -3.84% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 194.01% vs -51.78% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 3.26% vs -4.34% in Mar 2025
YoY Growth in year ended Mar 2026 is 167.47% vs -43.54% in Mar 2025